AstraZeneca rose Third place in the ranking of pharmaceutical companies with the best reputation in Spain The ninth edition of the Health Reputation Monitor (MRS) report is the only independent study that analyzes the reputation of the entire Spanish healthcare system and includes professional bodies of doctors and nurses, as well as patient associations and health journalists.
With total 8,107 points, the company moved up one spot from the previous edition, with AstraZeneca’s chairman, Rick R. Suárez, coming in at fifth place, topping the list of business leaders with the best reputations in the pharmaceutical industry. The company also entered the T.operation 10 companies pharmaceutical More attractive Working in Spain in 2022.
“This milestone represents The best recognition of our strengthened commitment to Spaina has established itself as a key country in our global growth strategy, being the first country in Europe in the number of clinical trials within the organisation. We have a firm will on this matter to continue collaborating with the entire healthcare ecosystem “Together promote the development of and access to innovative treatments that will transform patients’ lives and co-create solutions that will contribute to improving health outcomes and protecting our healthcare system,” said AstraZeneca president Rick Suárez.
AstraZeneca ranked first in the analysis according to treatment areas Doctorate in Family and Community Medicine and Nephrology, as the best-reputed and most innovative company, reaffirms its commitment to contributing to transforming the approach to high-impact pathologies such as chronic kidney disease. At the same time, evolution was emphasized with special reference. In the fields of Oncology and HematologyRecognizing the company’s commitment to revolutionizing the cancer treatment paradigm. Regarding the most promising drugs indicated by MRS, Enhertu was recognized as the drug providing the greatest therapeutic effect in its field. Oncology, Tezspire in Pulmonology, Saphnelo in Rheumatology and Lynparza in Urology.
AstraZeneca has significantly intensified its commitment to Spain and is now It has more than 1,300 employees in Madrid and Barcelona.. AstraZeneca conducted approximately 472 clinical studies involving more than 4,500 patients in 2022 and recently opened a new European R&D Center in Barcelona, from where it aims to accelerate the research and development of next-generation innovative treatments in the following areas. Department of Oncology, Rare Diseases, Cardiovascular, Kidney and Metabolism, Respiratory and Immunology and Vaccines and Immunotherapies
To prepare the study, MRS evaluated different actors in the healthcare system using the following sample: 223 hospital administrators and managers, 4,312 doctors, 532 patient associations, 110 health journalists, 80 members of the public health administration, 82 pharmaceutical laboratory managers and 70 hospital pharmacy managers.